16.05.2021, 1592 Zeichen
Agrana: In the 2020|21 financial year, fruit-, starch- and sugar company Agrana Beteiligungs-AG achieved a slight increase in Group revenue to Euro 2,547.0 mn. Operating profit (EBIT), at Euro 78.7 mn, rose 17.6% from the prior year. In the year under review, the Covid-19 pandemic was the defining factor for all business segments. In the Fruit segment, earnings of the fruit preparations business were up from a year ago despite one-off effects. In the fruit juice concentrate business, by contrast, poor apple harvests coincided with pandemic-related weak demand, especially in the food service and tourism sectors, which led to a significantly reduced earnings performance. In the Starch segment, reduced starch volumes sold to the graphic paper industry (the print sector) were offset by increased sales to corrugated cardboard manufacturers (packaging). Starch margins on balance were lower for demand reasons and the segment's operating performance was thus down from the prior year. In the Sugar segment, higher sugar prices and volumes contributed to a significant year-on-year improvement in the - albeit still negative - bottom line. "Despite the extraordinary conditions created by the Covid-19 pandemic, we delivered solid results in the last financial year. Overall, what is once again clear is that our stable business performance is due in large part to the diversification of our business segments," says Agrana Chief Executive Officer Johann Marihart.
Agrana: weekly performance:
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (11/05/2021)
kapitalmarkt-stimme.at daily voice 13/365: Die KESt-Behaltefrist, warum sie das heisseste Thema ist und eine kurze Frist her muss
Aktien auf dem Radar:Kapsch TrafficCom, Austriacard Holdings AG, EuroTeleSites AG, Flughafen Wien, Warimpex, Mayr-Melnhof, Erste Group, ATX, ATX Prime, ATX TR, OMV, Wienerberger, Cleen Energy, DO&CO, Pierer Mobility, Stadlauer Malzfabrik AG, Semperit, Strabag, Josef Manner & Comp. AG, Agrana, Amag, Rosenbauer, Oberbank AG Stamm, RHI Magnesita, EVN, Palfinger, Österreichische Post, Telekom Austria, Uniqa, VIG.
Croma
Croma Pharma® ist ein österreichisches Familienunternehmen mit Sitz in Leobendorf. Das Unternehmen ist auf die industrielle Fertigung von Hyaluronsäure-Spritzen spezialisiert und zählt in diesem Bereich europaweit zu den führenden Experten. Das Unternehmen setzt mit eigenen Marken auf die Wachstumssparte der minimalinvasiven ästhetischen Medizin.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab.
Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.
Newsletter abonnieren
Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)
per Newsletter erhalten